NEUN yields 2000000.00% · ORCC yields 9.79%● Live data
📍 NEUN pulled ahead of the other in Year 1
Combined, NEUN + ORCC cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NEUN + ORCC for your $10,000?
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.
Full NEUN Calculator →Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.
Full ORCC Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.